Discovery of substituted pyrazol-4-yl pyridazinone derivatives as novel c-Met kinase inhibitors
- 11 January 2016
- journal article
- Published by Springer Nature in Archives of Pharmacal Research
- Vol. 39 (4) , 453-464
Abstract
A series of pyridazin-3-one substituted with morpholino-pyrimidine derivatives was synthesized and evaluated as tyrosine kinase inhibitors against c-Met enzyme, and anti-proliferative activities of Hs746T human gastric cancer cell line. Most of compounds exhibited good biological activity, while compound 10, 12a, 14a displayed excellent c-Met enzyme inhibitory activities and Hs746T cell-based activities.Keywords
This publication has 16 references indexed in Scilit:
- Discovery of substituted 6-pheny-3H-pyridazin-3-one derivatives as novel c-Met kinase inhibitorsBioorganic & Medicinal Chemistry Letters, 2014
- MET inhibitors start on road to recoveryNature Reviews Drug Discovery, 2014
- Comprehensive molecular profiling of lung adenocarcinomaNature, 2014
- Targeting Receptor Tyrosine Kinase MET in Cancer: Small Molecule Inhibitors and Clinical ProgressJournal of Medicinal Chemistry, 2013
- Targeting MET in cancer: rationale and progressNature Reviews Cancer, 2012
- Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal–Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)Journal of Medicinal Chemistry, 2011
- Showering c-MET-dependent cancers with drugsCurrent Opinion in Genetics & Development, 2008
- MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 SignalingScience, 2007
- Invasive growth: a MET-driven genetic programme for cancer and stem cellsNature Reviews Cancer, 2006
- c-Met as a target for human cancer and characterization of inhibitors for therapeutic interventionCancer Letters, 2005